B+
Bull case
25%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
IKT
Inhibikase TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
First-patient enrollment in IMPROVE-PAH confirms the program has moved from planning into execution, and the 10-K shows $178.8 million of cash, cash equivalents, and marketable securities with management stating this funds normal operations for at least twelve months from the March 26, 2026 filing date [#8-K-2026-04-07] [#10-K-2026-03-26]. At roughly a $243 million market cap, that leaves a relatively modest enterprise value for a single-asset Phase 3 PAH story if enrollment and safety hold up.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional capital may be required before full value realization despite current cash runway
Momentum
84
Value
41
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.50 · Bull $3.40 · Bear $0.70Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $6.00
Why
Momentum84 · Δ7d -
Value41 · Δ7d 0.0
Sentiment29 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Additional capital may be required before full value realization despite current cash runway
- • Global Phase 3 enrollment and site-activation execution risk
- • This remains a single-program small-cap biotech with meaningful execution and financing risk.
Catalyst clock
2026-06-30
Early IMPROVE-PAH enrollment cadence update
Lead driver: Sentiment · See AI snapshot
Momentum
84
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
29
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 84.3 / Value 41.2 / Sentiment 29.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$333.49M
Beta
0.84
Shares Out
139.54M
P/E (TTM) · Derived
-4.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.56
Rev YoY
-100.0%
EPS YoY
+1.8%
Gross Margin
+67.0%
Op Margin
-23885.1%
Net Debt
-$178.76M
Current Ratio
15.82
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data